Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

NCT00082875 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

56

Enrollment

NIH

Sponsor class

Conditions

Stage III Melanoma
Stage IV Melanoma

Interventions

DRUG: cilengitide
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)